Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data

Pharmacology and Therapeutics

Volumn 139, Issue 1, 2013, Pages 51-59

  Kurosaki, Eiji ^a   Ogasawara, Hideaki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Glucosuria; Kidney; oral hypoglycemic agents; SGLT2 inhibitor; Sodium glucose cotransporter 2; Type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; HEMOGLOBIN A1C; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2; TOFOGLIFLOZIN;

ANTIDIABETIC ACTIVITY; B LYMPHOCYTE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSURIA; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENCE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84877922239     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.04.003     Document Type: Review

References (95)

1. P. Angulo Nonalcoholic fatty liver disease N Engl J Med 346 2002 1221 1231
2. C.J. Bailey, J.L. Gross, A. Pieters, A. Bastien, and J.F. List Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial Lancet 375 2010 2223 2233
3. J. Bolinder, O. Ljunggren, J. Kullberg, L. Johansson, J. Wilding, and A.M. Langkilde Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J Clin Endocrinol Metab 97 2012 1020 1031
4. Bristol-Myers Squibb, and AstraZeneca Background document; dapagliflozin Endocrinologic and Metabolic Drugs Advisory Committee, U.S. Food and Drug Administration 2011
5. J. Chen, S. Williams, S. Ho, H. Loraine, D. Hagan, and J.M. Whaley Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members Diabetes Ther 1 2010 57 92
6. J.J. Devenny, H.E. Godonis, S.J. Harvey, S. Rooney, M.J. Cullen, and M.A. Pelleymounter Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats Obesity (Silver Spring) 20 2012 1645 1652
7. J.R. Ehrenkranz, N.G. Lewis, C.R. Kahn, and J. Roth Phlorizin: A review Diabetes Metab Res Rev 21 2005 31 38
8. European Medicines Agency Assessment report Forxiga. Dapagliflozin. Procedure no.: EMEA/H/C/002322 2012
9. S.J. Farber, E.Y. Berger, and D.P. Earle Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose J Clin Invest 30 1951 125 129
10. E. Ferrannini, S.A. Veltkamp, R.A. Smulders, and T. Kadokura Renal glucose handling: Impact of chronic kidney disease and SGLT2 inhibition in patients with type 2 diabetes mellitus Diabetes Care 2013 10.2337/dc12-1503
11. V. Fonseca, E. Ferrannini, J. Wilding, W. Wilpshaar, P. Dhanjal, and G. Ball Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus J Diabetes Complications 2012 10.1016/j.jdiacomp.2012. 11.005
12. Food and Drug Adminstration FDA briefing document NDA 202293 Dapagliflozin tablets 5 and 10 mg 2011
13. Y. Fujimori, K. Katsuno, I. Nakashima, Y. Ishikawa-Takemura, H. Fujikura, and M. Isaji Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models J Pharmacol Exp Ther 327 2008 268 276
14. B. Gallwitz, and H.U. Haering Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas Diabetes Obes Metab 12 2010 1 11
15. A. Girach, D. Manner, and M. Porta Diabetic microvascular complications: Can patients at risk be identified? A review Int J Clin Pract 60 2006 1471 1483
16. K. Goto, A. Kashiwagi, K. Kazuta, S. Yoshida, E. Ueyama, and A. Utsuno Ipragliflozin reduces A1C and body weight in type 2 diabetes patients who have inadequate glycemic control on metformin alone: ILLUMINATE study American Diabetes Association, 72th Scientific Sessions. Philadelphia (PA) 2012
17. R. Grempler, L. Thomas, M. Eckhardt, F. Himmelsbach, A. Sauer, and D.E. Sharp Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors Diabetes Obes Metab 14 2012 83 90
18. S. Han, D.L. Hagan, J.R. Taylor, L. Xin, W. Meng, and S.A. Biller Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats Diabetes 57 2008 1723 1729
19. P. Hovind, P. Rossing, R.J. Johnson, and H.H. Parving Serum uric acid as a new player in the development of diabetic nephropathy J Ren Nutr 21 2011 124 127
20. M. Imamura, K. Nakanishi, T. Suzuki, K. Ikegai, R. Shiraki, and T. Ogiyama Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus Bioorg Med Chem 20 2012 3263 3279
21. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, and M. Nauck Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
22. M. Isaji SGLT2 inhibitors: Molecular design and potential differences in effect Kidney Int Suppl 2011 S14 S19
23. Janssen R&D Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus Endocrinologic and Metabolic Drugs Advisory Committee, U.S. Food and Drug Administration 2013
24. D. Jones Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor Nat Rev Drug Discov 10 2011 645 646
25. T. Kadokura, M. Saito, A. Utsuno, K. Kazuta, S. Yoshida, and S. Kawasaki Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects Diabetol Int 2 2011 172 182
26. T. Kadowaki, S. Ikeda, Y. Takano, O. Cynshi, A.D. Christ, and V. Boerlin Tofogliflozin, a novel and selective SGLT2 inhibitor improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled on stable metformin or diet and exercise alone American Diabetes Association, 72th Scientific Sessions. Philadelphia (PA) 2012
27. B.B. Kahn, G.I. Shulman, R.A. DeFronzo, S.W. Cushman, and L. Rossetti Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression J Clin Invest 87 1991 561 570
28. H. Kakinuma, T. Oi, Y. Hashimoto-Tsuchiya, M. Arai, Y. Kawakita, and Y. Fukasawa (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1- thio-d-glucito l (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment J Med Chem 53 2010 3247 3261
29. Y. Kanai, W.S. Lee, G. You, D. Brown, and M.A. Hediger The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose J Clin Invest 93 1994 397 404
30. A. Kashiwagi, T. Shiga, N. Akiyama, K. Kazuta, H. Ogasawara, and S. Yoshida Ipragliflozin reduced HbA1c and body weight in Japanese type 2 diabetes mellitus patients who have inadequate glycaemic control on sulfonylurea or pioglitazone alone The European Association for the Study of Diabetes, 48th Annual Meeting. Berlin, Germany 2012
31. A. Kashiwagi, Y. Takinami, K. Kazuta, S. Yoshida, A. Utsuno, and I. Nagase Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN study The European Association for the Study of Diabetes, 47th Annual Meeting. Lisbon, Portugal 2011
32. A. Kashiwagi, A. Utsuno, K. Kazuta, S. Yoshida, and S. Kageyama ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes mellitus American Diabetes Association, 70th Scientific Sessions. Orlando (FL) 2010
33. K. Katsuno, Y. Fujimori, Y. Takemura, M. Hiratochi, F. Itoh, and Y. Komatsu Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level J Pharmacol Exp Ther 320 2007 323 330
34. R.K. Kinne, and F. Castaneda SGLT inhibitors as new therapeutic tools in the treatment of diabetes Handb Exp Pharmacol 105-126 2011
35. T.F. Knight, H.O. Senekjian, S. Sansom, and E.J. Weinman Effects of intraluminal d-glucose and probenecid on urate absorption in the rat proximal tubule Am J Physiol 236 1979 F526 F529
36. B. Komoroski, N. Vachharajani, D. Boulton, D. Kornhauser, M. Geraldes, and L. Li Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Clin Pharmacol Ther 85 2009 520 526
37. B. Komoroski, N. Vachharajani, Y. Feng, L. Li, D. Kornhauser, and M. Pfister Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus Clin Pharmacol Ther 85 2009 513 519
38. E. Kurosaki, A. Tahara, M. Yokono, D. Yamajuku, T. Takasu, and M. Imamura In vitro and in vivo pharmacological properties of ASP1941, a novel, potent and selective SGLT2 inhibitor American Diabetes Association, 70th Scientific Sessions. Orlando (FL) 2010
39. E. Kurosaki, T. Takasu, S. Yamazaki, K. Koide, N. Maeda, and A. Hastings Ipragliflozin (ASP1941), a novel SGLT2 inhibitor, demonstrates beneficial effects on nonalcoholic fatty liver disease in animal models American Diabetes Association, 72th Scientific Sessions. Philadelphia (PA) 2012
40. +/glucose cotransporter. Re-evaluation of function and distribution of expression J Biol Chem 269 1994 12032 12039
41. Y.J. Lee, Y.J. Lee, and H.J. Han Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells Kidney Int Suppl S27-35 2007
42. Y. Liang, K. Arakawa, K. Ueta, Y. Matsushita, C. Kuriyama, and T. Martin Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models PLoS One 7 2012 e30555
43. J.F. List, V. Woo, E. Morales, W. Tang, and F.T. Fiedorek Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 32 2009 650 657
44. J.J. Liu, T. Lee, and R.A. DeFronzo Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 61 2012 2199 2204
45. G. Luippold, T. Klein, M. Mark, and R. Grempler Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus Diabetes Obes Metab 14 2012 601 607
46. F.R. Macdonald, J.E. Peel, H.B. Jones, R.M. Mayers, L. Westgate, and J.M. Whaley The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats Diabetes Obes Metab 12 2010 1004 1012
47. W. Meng, B.A. Ellsworth, A.A. Nirschl, P.J. McCann, M. Patel, and R.N. Girotra Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes J Med Chem 51 2008 1145 1149
48. A. Mitrakou Kidney: Its impact on glucose homeostasis and hormonal regulation Diabetes Res Clin Pract 93 Suppl. 1 2011 S66 S72
49. C.E. Mogensen Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects Scand J Clin Lab Invest 28 1971 101 109
50. S. Mudaliar, D.A. Armstrong, A.A. Mavian, R. O'Connor-Semmes, P.K. Mydlow, and J. Ye Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes Diabetes Care 35 2012 2198 2200
51. S. Mudaliar, R.R. Henry, G. Boden, S. Smith, A.G. Chalamandaris, and N. Iqbal Changes in insulin sensitivity as measured by glucose disposal rate and acute insulin secretion with the sodium glucose co-transporter 2 inhibitor dapagliflozin The European Association for the Study of Diabetes, 47th Annual Meeting. Lisbon, Portugal 2011
52. S. Nomura, S. Sakamaki, M. Hongu, E. Kawanishi, Y. Koga, and T. Sakamoto Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus J Med Chem 53 2010 6355 6360
53. Y. Ohtake, T. Sato, T. Kobayashi, M. Nishimoto, N. Taka, and K. Takano Discovery of tofogliflozin, a novel C-Arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes J Med Chem 55 2012 7828 7840
54. +-glucose cotransporters, may provide a novel approach to treating diabetes Diabetes 48 1999 1794 1800
55. K.L. Ong, B.M. Cheung, L.Y. Wong, N.M. Wat, K.C. Tan, and K.S. Lam Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004 Ann Epidemiol 18 2008 222 229
56. S. O'Rahilly Human obesity and insulin resistance: Lessons from experiments of nature Biochem Soc Trans 35 2007 33 36
57. L. Pirola, A. Balcerczyk, J. Okabe, and A. El-Osta Epigenetic phenomena linked to diabetic complications Nat Rev Endocrinol 6 2010 665 675
58. J. Plutzky Macrovascular effects and safety issues of therapies for type 2 diabetes Am J Cardiol 108 2011 25B 32B
59. D. Polidori, S. Sha, S. Mudaliar, T.P. Ciaraldi, A. Ghosh, and N. Vaccaro Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion American Diabetes Association, 72th Scientific Sessions. Philadelphia (PA) 2012
60. D. Polidori, Y. Zhao, M. Alba, and E. Ferrannini Treatment with canagliflozin (CANA), a Sodium Glucose Co-transporter 2 (SGLT2) inhibitor, for 26 weeks improves indices of beta-cell function (BCF) American Diabetes Association, 72th Scientific Sessions. Philadelphia (PA) 2012
61. H. Rahmoune, P.W. Thompson, J.M. Ward, C.D. Smith, G. Hong, and J. Brown Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes Diabetes 54 2005 3427 3434
62. J. Rosenstock, N. Aggarwal, D. Polidori, Y. Zhao, D. Arbit, and K. Usiskin Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 35 2012 1232 1238
63. J. Rosenstock, M. Vico, L. Wei, A. Salsali, and J.F. List Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy Diabetes Care 35 2012 1473 1478
64. L. Rossetti, A. Giaccari, and R.A. DeFronzo Glucose toxicity Diabetes Care 13 1990 610 630
65. L. Rossetti, G.I. Shulman, W. Zawalich, and R.A. DeFronzo Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats J Clin Invest 80 1987 1037 1044
66. L. Rossetti, D. Smith, G.I. Shulman, D. Papachristou, and R.A. DeFronzo Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats J Clin Invest 79 1987 1510 1515
67. R. Santer, M. Kinner, C.L. Lassen, R. Schneppenheim, P. Eggert, and M. Bald Molecular analysis of the SGLT2 gene in patients with renal glucosuria J Am Soc Nephrol 14 2003 2873 2882
68. S.L. Schwartz, B. Akinlade, S. Klasen, D. Kowalski, W. Zhang, and W. Wilpshaar Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus Diabetes Technol Ther 13 2011 1219 1227
69. Y. Seino, T. Sasaki, A. Fukatsu, Y. Samukawa, S. Sakai, and T. Watanabe Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus American Diabetes Association, 72th Scientific Sessions. Philadelphia (PA) 2012
70. S. Sha, D. Devineni, A. Ghosh, D. Polidori, S. Chien, and D. Wexler Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects Diabetes Obes Metab 13 2011 669 672
71. P. Shah, and S. Mudaliar Pioglitazone: Side effect and safety profile Expert Opin Drug Saf 9 2010 347 354
72. M.D. Skeith, L.A. Healey, and R.E. Cutler Effect of phloridzin on uric acid excretion in man Am J Physiol 219 1970 1080 1082
73. B.W. Smith, and L.A. Adams Nonalcoholic fatty liver disease and diabetes mellitus: Pathogenesis and treatment Nat Rev Endocrinol 7 2011 456 465
74. K. Strojek, K.H. Yoon, V. Hruba, M. Elze, A.M. Langkilde, and S. Parikh Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 13 2011 928 938
75. M. Suzuki, K. Honda, M. Fukazawa, K. Ozawa, H. Hagita, and T. Kawai Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice J Pharmacol Exp Ther 341 2012 692 701
76. A. Tahara, E. Kurosaki, M. Yokono, D. Yamajuku, R. Kihara, and Y. Hayashizaki Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo Naunyn Schmiedebergs Arch Pharmacol 385 2012 423 436
77. T. Takahashi, M. Onishi, H. Yamashita, E. Gunji, T. Takeda, and H. Tomoike Luseogliflozin (TS-071), a novel, potent and selective SGLT2 inhibitor, prevents diabetic retinopathy in rats American Diabetes Association, 72th Scientific Sessions. Philadelphia (PA) 2012
78. T. Takasu, Y. Hayashizaki, J. Hirosumi, H. Minoura, N. Amino, and E. Kurosaki Ipragliflozin, a novel SGLT2-selective inhibitor, improves glycemic control and reduces body fat in the diabetic Goto-Kakizaki (GK) rats American Diabetes Association, 72th Scientific Sessions. Philadelphia (PA) 2012
79. T. Takasu, Y. Hayashizaki, K. Mitsuoka, M. Yokono, R. Kihara, and S. Miyoshi ASP1941, a novel SGLT2-selective inhibitor, exerts anti-obesity effects by increasing fatty acid oxidation in diet-induced obesity rats American Diabetes Association, 71th Scientific Sessions. San Diego (CA) 2011
80. T. Takasu, A. Tahara, M. Yokono, Y. Hayashizaki, E. Kurosaki, and M. Imamura ASP1941, a novel, potent and selective SGLT2 inhibitor, improves hemoglobin A1c and symptoms of diabetes in animal models American Diabetes Association, 70th Scientific Sessions. Orlando (FL) 2010
81. L. Thomas, R. Grempler, M. Eckhardt, F. Himmelsbach, A. Sauer, and T. Klein Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats Diabetes Obes Metab 14 2012 94 96
82. S.C. Thomson, T. Rieg, C. Miracle, H. Mansoury, J. Whaley, and V. Vallon Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat Am J Physiol Regul Integr Comp Physiol 302 2012 R75 R83
83. A. Tsapas, D. Vassilakou, E. Athanasiadou, and T. Karagiannis Systematic review and meta-analysis of the efficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes mellitus The European Association for the Study of Diabetes, 48th Annual Meeting. Berlin, Germany 2012
84. +-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats Life Sci 76 2005 2655 2668
85. V. Vallon, K.A. Platt, R. Cunard, J. Schroth, J. Whaley, and S.C. Thomson SGLT2 mediates glucose reabsorption in the early proximal tubule J Am Soc Nephrol 22 2011 104 112
86. V. Vallon, and S.C. Thomson Renal function in diabetic disease models: The tubular system in the pathophysiology of the diabetic kidney Annu Rev Physiol 74 2012 351 375
87. S. van Dieren, J.W. Beulens, Y.T. van der Schouw, D.E. Grobbee, and B. Neal The global burden of diabetes and its complications: An emerging pandemic Eur J Cardiovasc Prev Rehabil 17 Suppl. 1 2010 S3 S8
88. S.A. Veltkamp, T. Kadokura, W.J. Krauwinkel, and R.A. Smulders Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects Clin Drug Investig 31 2011 839 851
89. W.N. Washburn Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents Expert Opin Ther Pat 19 2009 1485 1499
90. J.P. Wilding, E. Ferrannini, V.A. Fonseca, W. Wilpshaar, P. Dhanjal, and A. Houzer Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: A dose-finding study Diabetes Obes Metab 2012 10.1111/dom.12038
91. H.J. Woerle, E. Ferrannini, A. Berk, M. Manun'ebo, S. Pinnetti, and U.C. Broedl Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetes American Diabetes Association, 72th Scientific Sessions. Philadelphia (PA) 2012
92. E.M. Wright Renal Na(+)-glucose cotransporters Am J Physiol Renal Physiol 280 2001 F10 F18
93. E.M. Wright, D.D. Loo, and B.A. Hirayama Biology of human sodium glucose transporters Physiol Rev 91 2011 733 794
94. E.M. Wright, E. Turk, and M.G. Martin Molecular basis for glucose-galactose malabsorption Cell Biochem Biophys 36 2002 115 121
95. K. Yamamoto, S. Uchida, K. Kitano, N. Fukuhara, L. Okumura-Kitajima, and E. Gunji TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity Br J Pharmacol 164 2011 181 191